Navigation Links
Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Date:2/5/2009

Repligen Corporation. "Our financial resources will allow us to continue to advance our clinical programs and aggressively pursue the acquisition of new product candidates for our pipeline in 2009."

For the nine-month period ended December 31, 2008, total revenue was $24,768,000 compared to $15,996,000 for the same period in fiscal year 2008. Operating expenses for the nine-month period were $17,672,000, compared to $16,409,000, exclusive of the net gain of $40,170,000 from a litigation settlement, for the same period in fiscal year 2008. Net income for the nine-month period was $8,439,000 or $0.27 per diluted share compared to net income of $40,304,000 or $1.29 per diluted share in the same period in fiscal year 2008.

Corporate Update

RG1068 for Imaging of the Pancreas

We are currently enrolling patients in a Phase 3 clinical trial of RG1068, synthetic human secretin, designed to assess the ability of RG1068 enhanced magnetic resonance imaging (MRI) to improve the detection of pancreatic duct abnormalities compared to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the diagnosis and treatment of diseases such as acute and chronic pancreatitis. This study is being conducted at approximately 25 clinical sites within the U.S. and Canada and will enroll approximately 250 patients. The FDA has granted this program Fast Track Designation, a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need. There are more than 300,000 procedures conducted in the U.S. and Europe each year that may benefit from enhancement with RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
3. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
4. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
5. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
6. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
7. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
10. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... MILAN , October 27, 2014 ... the right to produce, exhibit and sell its ... sought to impeach their patent.      ... After four years of fighting, the definitive judgement ... designs and produces innovative and accessible hi-tech prostheses ...
(Date:10/27/2014)... October 27, 2014 The “Molecular ... Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End ... Service, Software) - Global Forecast to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/27/2014)... The report “Smart Highway Market ... Communication, Monitoring), and by Display (Variable Message Signs, ... the global market into various sub-segments with in-depth ... the drivers and restraints for this market with ... 75 market tables and 37 figures spread through ...
(Date:10/27/2014)... 2014 Investor-Edge has initiated coverage ... NBIX ), Insmed Inc. (NASDAQ: INSM ... Dyax Corporation (NASDAQ: DYAX ), and Oncothyreon ... can be accessed at: http://investor-edge.com/register . ... at 4,483.72, up 0.69%, the Dow Jones Industrial Average ...
Breaking Biology Technology:Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... 17 Alfacell Corporation,(Nasdaq: ACEL ) announced ... the,engagement of Oppenheimer & Co. as a financial ... strategic alternatives to enhance,shareholder value, including a possible ... but not be limited to, strategic partnership,transactions., ...
... (MBI) has been awarded a $625,000 contract under ... development of a Universal Sample,Preparation Module (USPM). The ... SBIR firms that have Phase II projects that ... products., MBI,s project will develop a Universal ...
... September 17 Sangui BioTech,International, Inc., is currently preparing ... 30, 2008). The ensuing report on form,10KSB will be ... course. It will be,included in the proxy materials for ... a letter by the SEC. Subsequently, the,shareholders, meeting will ...
Cached Biology Technology:Alfacell Hires Advisors to Advance Strategic Alternatives 2Alfacell Hires Advisors to Advance Strategic Alternatives 3Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program 2Sangui Bio Tech International Inc. Shareholders' Meeting Delayed to Include FY 2008 Report 2
(Date:10/28/2014)... German . ... sufficient food when times are lean? By studying wild ... researchers of the Max Planck Institute for Evolutionary Anthropology ... great apes can acquire extra energy needed to maintain ... sleeping nests more en route to breakfast sites containing ...
(Date:10/28/2014)... Singapore (NTU Singapore) will be building a hybrid ... sources. , The first in the region, the ... of solar, wind, tidal-current, diesel, storage and power-to-gas ... together. , To be built under the new ... hybrid micro-grid will be located offshore at Semakau ...
(Date:10/27/2014)... Ga. – Multiple times each day, about a third ... pressure – for at least an hour after the ... , Now they want to know how chronic mental ... response so they can determine the best ways to ... sodium is bad for you – these patients have ...
Breaking Biology News(10 mins):The early chimp gets the fig 2The early chimp gets the fig 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3Researchers look for the best way to help shake too much sodium 2Researchers look for the best way to help shake too much sodium 3Researchers look for the best way to help shake too much sodium 4
... and the debriefing today, the Russian State Commission has given ... CEST. Today,s go-ahead marks the last milestone along the ... tiny variations in the thickness of ice floating in the ... land, the mission will provide scientists with hard evidence on ...
... of Pittsburgh provides the first identification of a human ... in products from electronics to plasticsand in laboratory tests ... to the tiny components, according to findings published online ... open the door to the use of carbon nanotubes ...
... After years of preparation and anticipation, scientists who discover ... key question about Alzheimer,s disease: Will drugs that block ... called amyloid-beta slow the progression of the devastating disease? ... Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
Cached Biology News:CryoSat-2 ready for launch 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
... are designed for sequencing inserts cloned into ... or T3 RNA polymerase promoters, or lambda ... at a concentration of 0.1 µg/µl in ... DNA sequencing reactions using SequiTherm™ EXCEL™ II ...
BD BioCoat Fibronectin 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of human fibronectin....
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (C6671) or contact customer ... yes Surface area 148 cm 2 ...
Biology Products: